Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by:
Washington Neuropsychology Research Group
ClinicalTrials.gov Identifier:
NCT00914758
First received: June 3, 2009
Last updated: June 4, 2009
Last verified: June 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: December 2011
  Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)